SciClone Pharmaceuticals (SCLN) was Initiated by Maxim Group to “Buy” and the brokerage firm has set the Price Target at $14. Maxim Group advised their investors in a research report released on Nov 29, 2016.
On the company’s financial health, SciClone Pharmaceuticals reported $0.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.14 according to the earnings call on Nov 9, 2015. Analyst had a consensus of $0.12. The company had revenue of $42.90 million for the quarter, compared to analysts expectations of $40.61 million. The company’s revenue was up 25.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.17 EPS.
SciClone Pharmaceuticals opened for trading at $10.2 and hit $10.25 on the upside on Friday, eventually ending the session at $10.2, with a gain of 0.49% or 0.05 points. The heightened volatility saw the trading volume jump to 2,28,059 shares. Company has a market cap of $521 M.
In a different news, on Nov 23, 2016, Friedhelm Blobel (President & CEO) sold 70,000 shares at $10.22 per share price. According to the SEC, on Oct 27, 2016, Wilson Wai-shun Cheung (CFO & Senior VP, Finance) sold 149,962 shares at $10.00 per share price. On Aug 30, 2016, Nancy T Chang (director) sold 25,040 shares at $10.30 per share price, according to the Form-4 filing with the securities and exchange commission.
SciClone Pharmaceuticals Inc. (SciClone) is a pharmaceutical company. The Company operates in two geographic segments including China and the rest of the world (the United States and Hong Kong). The Company’s lead product ZADAXIN (thymalfasin) is used for the treatment of hepatitis B virus (HBV) hepatitis C (HCV) as a vaccine adjuvant and certain cancers. Its development portfolio includes Angiomax an anticoagulant indicated in patients undergoing percutaneous coronary intervention (PCI); Neucardin therapeutic drug for the treatment of patients with intermediate to advanced chronic heart failure (CHF); Loramyc a mucoadhesive tablet formulation of miconazole lauriad to treat oropharyngeal candidiasis; Cleviprex a third-generation dihydropyridine calcium channel blocker for the reduction of blood pressure; ProFlow to treat peripheral arterial disease (PAD) and other indications and RapidFilm an oral film formulation of ondansetron to treat nausea induced by chemotherapy.